![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PPP2R3B |
Gene summary for PPP2R3B |
![]() |
Gene information | Species | Human | Gene symbol | PPP2R3B | Gene ID | 28227 |
Gene name | protein phosphatase 2 regulatory subunit B''beta | |
Gene Alias | NYREN8 | |
Cytomap | X | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q9Y5P8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
28227 | PPP2R3B | C38 | Human | Oral cavity | OSCC | 7.16e-03 | 3.81e-01 | 0.172 |
28227 | PPP2R3B | C46 | Human | Oral cavity | OSCC | 6.28e-11 | 2.63e-01 | 0.1673 |
28227 | PPP2R3B | C51 | Human | Oral cavity | OSCC | 1.42e-05 | 2.75e-01 | 0.2674 |
28227 | PPP2R3B | C57 | Human | Oral cavity | OSCC | 3.67e-02 | 1.69e-01 | 0.1679 |
28227 | PPP2R3B | LN22 | Human | Oral cavity | OSCC | 9.96e-04 | 5.78e-01 | 0.1733 |
28227 | PPP2R3B | LN46 | Human | Oral cavity | OSCC | 3.60e-06 | 3.04e-01 | 0.1666 |
28227 | PPP2R3B | SYSMH2 | Human | Oral cavity | OSCC | 1.93e-12 | 3.09e-01 | 0.2326 |
28227 | PPP2R3B | SYSMH3 | Human | Oral cavity | OSCC | 3.85e-15 | 5.38e-01 | 0.2442 |
28227 | PPP2R3B | SYSMH5 | Human | Oral cavity | OSCC | 1.23e-02 | 2.48e-01 | 0.0647 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa051659 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0407114 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa041516 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa041529 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
hsa0516514 | Oral cavity | OSCC | Human papillomavirus infection | 200/3704 | 331/8465 | 3.83e-10 | 4.93e-09 | 2.51e-09 | 200 |
hsa0407115 | Oral cavity | OSCC | Sphingolipid signaling pathway | 82/3704 | 121/8465 | 6.97e-08 | 5.08e-07 | 2.58e-07 | 82 |
hsa0415113 | Oral cavity | OSCC | PI3K-Akt signaling pathway | 185/3704 | 354/8465 | 6.26e-04 | 1.86e-03 | 9.49e-04 | 185 |
hsa0415212 | Oral cavity | OSCC | AMPK signaling pathway | 71/3704 | 121/8465 | 6.29e-04 | 1.86e-03 | 9.49e-04 | 71 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PPP2R3B | SNV | Missense_Mutation | rs757683941 | c.1050N>C | p.Lys350Asn | p.K350N | Q9Y5P8 | protein_coding | deleterious(0) | possibly_damaging(0.601) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PPP2R3B | SNV | Missense_Mutation | novel | c.895N>A | p.Glu299Lys | p.E299K | Q9Y5P8 | protein_coding | deleterious(0) | possibly_damaging(0.766) | TCGA-C8-A8HP-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | 5-fluorouracil | CR |
PPP2R3B | SNV | Missense_Mutation | novel | c.1290N>T | p.Glu430Asp | p.E430D | Q9Y5P8 | protein_coding | tolerated(0.06) | benign(0.408) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PPP2R3B | SNV | Missense_Mutation | novel | c.907G>A | p.Asp303Asn | p.D303N | Q9Y5P8 | protein_coding | deleterious(0.02) | probably_damaging(0.913) | TCGA-MA-AA41-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
PPP2R3B | SNV | Missense_Mutation | novel | c.814N>A | p.Ala272Thr | p.A272T | Q9Y5P8 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PPP2R3B | SNV | Missense_Mutation | c.761N>T | p.Ala254Val | p.A254V | Q9Y5P8 | protein_coding | deleterious(0.02) | possibly_damaging(0.701) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
PPP2R3B | SNV | Missense_Mutation | c.1291N>A | p.Ala431Thr | p.A431T | Q9Y5P8 | protein_coding | tolerated(0.22) | benign(0.011) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
PPP2R3B | SNV | Missense_Mutation | c.761N>T | p.Ala254Val | p.A254V | Q9Y5P8 | protein_coding | deleterious(0.02) | possibly_damaging(0.701) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
PPP2R3B | SNV | Missense_Mutation | rs374748842 | c.400C>T | p.Arg134Cys | p.R134C | Q9Y5P8 | protein_coding | tolerated(0.12) | benign(0.003) | TCGA-CK-5916-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PPP2R3B | SNV | Missense_Mutation | rs760244257 | c.887N>T | p.Ala296Val | p.A296V | Q9Y5P8 | protein_coding | deleterious(0.04) | benign(0.383) | TCGA-G4-6309-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | xeloda | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |